• 1
    Gharavi AE, Wilson WA. Antiphospholipid antibodies. In: WallaceDJ, HahnBH, editors. Lupus erythematosus. 5th ed. Williams and Wilkins; 1997. p. 47191.
  • 2
    Sammaritano LR, Gharavi AE, Lockshin MD. Antiphospholipid antibody syndrome: immunologic and clinical aspects. Semin Arthritis Rheum 1990; 20: 8196.
  • 3
    Harris EN, Gharavi AE, Hughes GR. Antiphospholipid antibodies. Clin Rheum Dis 1985; 11: 591609.
  • 4
    Gharavi AE, Harris EN, Asherson RA, Hughes GR. Anticardiolipin antibodies: isotype distribution and phospholipid specificity. Ann Rheum Dis 1987; 46: 16.
  • 5
    Harris EN, Gharavi AE, Boey ML, Patel MB, Mackworth-Young CG, Loizou S, et al. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 1983; 2: 12114.
  • 6
    McNeil HP, Simpson RJ, Chesterman CJ, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes lipid-binding inhibitor of coagulation: β2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A 1990; 87: 41204.
  • 7
    Galli M, Comfurius P, Maassen C, Hemker HC, de Baets MH, van Breda-Vriesman PJ, Barbui T, et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335: 15447.
  • 8
    Matsuura H, Igarashi T, Fujimoto M, Ichikawa K, Koike T. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease [letter]. Lancet 1990; 336: 1778.
  • 9
    Schousboe I. β 2-glycoprotein I: a plasma inhibitor of the contact activation of the intrinsic blood coagulation pathway. Blood 1985; 66: 108691.
  • 10
    Kato H, Enjyoji K. Amino acid sequence and location of the disulfide bonds in bovine β 2 glycoprotein I: the presence of five Sushi domains. Biochemistry 1991; 30: 1168794.
  • 11
    Hunt J, Krilis S. The fifth domain of β 2-glycoprotein I contains a phospholipid binding site (Cys281-Cys288) and a region recognized by anticardiolipin antibodies. J Immunol 1994; 152: 6539.
  • 12
    Gharavi AE, Sammaritano LR, Wen J, Elkon KB. Induction of antiphospholipid autoantibodies by immunization with β 2 glycoprotein I (apolipoprotein H). J Clin Invest 1992; 90: 11059.
  • 13
    Gharavi AE, Sammaritano LR, Bovastro JL Jr, Wilson WA. Specificities and characteristics of β 2 glycoprotein I-induced antiphospholipid antibodies. J Lab Clin Med 1995; 125: 7758.
  • 14
    Pierangeli SS, Harris EN. Induction of phospholipid-binding antibodies in mice and rabbits by immunization with human β 2 glycoprotein 1 or anticardiolipin antibodies alone. Clin Exp Immunol 1993; 93: 26972.
  • 15
    Blank M, Fadein D, Tincani A, Kopolovic J, Goldberg I, Gilburd B, et al. Immunization with anticardiolipin cofactor (β-2-glycoprotein I) induces experimental antiphospholipid syndrome in naive mice. J Autoimmun 1994; 7: 44155.
  • 16
    Aron AL, Cuellar ML, Brey RL, McKeown S, Espinoza LR, Shoenfeld Y, et al. Early onset of autoimmunity in MRL/++ mice following immunization with β 2 glycoprotein I. Clin Exp Immunol 1995; 101: 7881.
  • 17
    Garcia CO, Kanbour-Shakir A, Tang H, Molina JF, Espinoza LR, Gharavi AE. Induction of experimental antiphospholipid antibody syndrome in PL/J mice following immunization with β 2 GPI. Am J Reprod Immunol 1997; 37: 11824.
  • 18
    Pierangeli SS, Liu SW, Anderson G, Barker JH, Harris EN. Thrombogenic properties of murine anti-cardiolipin antibodies induced by β 2 glycoprotein 1 and human immunoglobulin G antiphospholipid antibodies. Circulation 1996; 94: 174651.
  • 19
    Gharavi AE, Pierangeli SS, Gharavi EE, Hua T, Liu XW, Barker JH, et al. Thrombogenic properties of antiphospholipid antibodies do not depend on their binding to β 2 glycoprotein 1 βGP1 alone. Lupus 1998; 7: 3416.
  • 20
    Gharavi AE, Pierangeli SS, Colden-Stanfield M, Liu XW, Espinola RG, Harris EN. GDKV-induced antiphospholipid antibodies enhance thrombosis and activate endothelial cells in vivo and in vitro. J Immunol 1999; 163: 29227.
  • 21
    Gharavi EE, Chaimovich H, Cucurull E, Celli CM, Tang H, Wilson WA, et al. Induction of antiphospholipid antibodies by immunization with viral and bacterial peptides. Lupus 1999; 8: 44955.
  • 22
    Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody to predefined specificity. Biotechnology 1975; 24: 5246.
  • 23
    Exner T, Rickard KA, Kronenberg H. A sensitive test demonstrating lupus anticoagulant and its behavioral patterns. Br J Haematol 1978; 40: 14350.
  • 24
    Damianovich M, Gilburd B, George J, Del Papa N, Afek A, Goldberg I, et al. Pathogenic role of anti-endothelial cell antibodies in vasculitis: an idiopathic experimental model. J Immunol 1996; 156: 494651.
  • 25
    Stockmans F, Deckmyn H, Gruwez J, Vermylen J, Acland R. Continuous quantitative monitoring of mural, platelet-dependent, thrombus kinetics in the crushed rat femoral vein. Thromb Haemost 1991; 65: 42531.
  • 26
    Pierangeli SS, Barker JH, Stikovac D, Ackerman D, Anderson G, Barquinero J, et al. Effect of human IgG antiphospholipid antibodies on an in vivo thrombosis model in mice. Thromb Haemost 1994; 17: 6704.
  • 27
    Pierangeli SS, Liu XW, Barker JH, Anderson G, Harris EN. Induction of thrombosis in a mouse model by IgG, IgM and IgA immunoglobulins from patients with the antiphospholipid syndrome. Thromb Haemost 1995; 74: 13617.
  • 28
    Liu X, Peter FW, Barker JH, Pierangeli SS, Harris EN, Anderson GL. Leukocyte-endothelium interaction in arterioles after ischemia and reperfusion. J Surg Res 1999; 87: 7784.
  • 29
    Pierangeli SS, Colden-Stanfield M, Liu X, Barker JH, Anderson GL, Harris EN. Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo. Circulation 1999; 99: 19972002.
  • 30
    Pierangeli SS, Espinola RG, Liu X, Harris EN. Thrombogenic effects of antiphospholipid antibodies are mediated by intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1 and P-selectin. Circ Res 2001; 88: 24550.
  • 31
    Harris EN, Chan JK, Asherson RA, Aber VR, Gharavi AE, Hughes GR. Thrombosis, recurrent fetal loss, and thrombocytopenia: predictive value of the anticardiolipin antibody test. Arch Intern Med 1986; 146: 21536.
  • 32
    Harris EN, Gharavi AE, Mackworth-Young CG, Patel BM, Derue G, Hughes GR. Lupoid sclerosis: a possible pathogenic role for antiphospholipid antibodies. Ann Rheum Dis 1985; 44: 2813.
  • 33
    Reverter JC, Tassies D, Font J, Khamashta MA, Ichikawa K, Cervera R, et al. Effects of human monoclonal anticardiolipin antibodies on platelet function and on tissue factor expression on monocytes. Arthritis Rheum 1998; 41: 14207.
  • 34
    Blank M, Shoenfeld Y, Cabilly S, Heldman Y, Fridkin M, Katchalski-Katzir E. Prevention of experimental antiphospholipid syndrome and endothelial cell activation by synthetic peptides. Proc Natl Acad Sci U S A 1999; 96: 51648.
  • 35
    Harris EN, Gharavi AE, Wasley GD, Hughes GR. Use of an enzyme-linked immunosorbent assay and of inhibition studies to distinguish between antibodies to cardiolipin from patients with syphilis or autoimmune disorders. J Infect Dis 1988; 157: 2331.
  • 36
    Costello PB, Green FA. Reactivity patterns of human anticardiolipin and other antiphospholipid antibodies in syphilitic sera. Infect Immun 1986; 51: 7715.
  • 37
    Levy RA, Gharavi AE, Sammaritano LR, Habina L, Qamar T, Lockshin MD. Characteristics of IgG antiphospholipid antibodies in patients with systemic lupus erythematosus and syphilis. J Immunol 1990; 17: 103641.
  • 38
    Fiallo P, Nunzi P, Cardo PP. B2 glycoprotein I-dependent anticardiolipin antibodies as a risk factor for reactions in borderline leprosy patients. Int J Lepr Other Mycobact Dis 1998; 66: 3878.
  • 39
    Durupt S, Rosselli S, Manchon J, Lopez M. Presence of antiphospholipid antibodies in Legionnaires' disease. Presse Med 1996; 25: 164959.
  • 40
    Galvez J, Martin I, Merino D, Pujol E. Thrombophlebitis in a patient with acute Q fever and anticardiolipin antibodies. Med Clin (Barc) 1997; 108: 3967.
  • 41
    Santiago MB, Cossermelli W, Tuma MF, Pinto MN, Oliveira RM. Anticardiolipin antibodies in patients with infectious diseases. Clin Rheumatol 1989; 8: 238.
  • 42
    Forastiero RR, Martinuzzo ME, Kordich LC, Carreras LO. Reactivity to β 2 glycoprotein I clearly differentiates anticardiolipin antibodies from antiphospholipid syndrome and syphilis. Thromb Haemost 1996; 75: 71720.
  • 43
    Mackworth-Young CG, Harris EN, Steere AC, Rizvi F, Malawista SE, Hughes GR, et al. Anticardiolipin antibodies in Lyme disease. Arthritis Rheum 1988; 31: 10526.
  • 44
    Catteau B, Delaporte E, Hachulla E, Piette F, Bergoend H. Mycoplasma infection with Stevens-Johnson syndrome and antiphospholipid antibodies: apropos of 2 cases. Rev Med Interne 1995; 16: 104.
  • 45
    Labarca JA, Rabaggliati RM, Radrigan FJ, Rojas PP, Perez CM, Ferres MV, et al. Antiphospholipid syndrome associated with cytomegalovirus infection: case report and review. Clin Infect Dis 1997; 24: 197200.
  • 46
    Manco-Johnson MJ, Nuss R, Key N, Moertel C, Jacobson K, Meech S, et al. Lupus anticoagulant and protein S deficiency in children with postvaricella purpura fulminans or thrombosis. J Pediatr 1996; 128: 31923.
  • 47
    Constans J, Guerin V, Couchouron A, Seigneur M, Ryman A, Blann AD, et al. Autoantibodies directed against phospholipids or human β 2-glycoprotein I in HIV-seropositive patients: relationship with endothelial activation and antimalonic dialdehyde antibodies. Eur J Clin Invest 1998; 28: 11522.
  • 48
    Herzenberg AM, Telford JJ, De Luca LG, Holden JK, Magil AB. Thrombotic microangiopathy associated with cryoglobulinemic membranoproliferative glomerulonephritis and hepatitis C. Am J Kidney Dis 1998; 31: 5216.
  • 49
    Poux JM, Jauberteau MO, Boudet R, Leroux-Robert C, Loizou F. Transient lupus anticoagulant induced by Epstein-Barr virus infections. Blood Coag Fibrinolysis 1991; 2: 7714.
  • 50
    Hojnik M, Gilburd B, Ziporen L, Blank M, Tomer Y, Scheinberg MA, et al. Anticardiolipin antibodies in infections are heterogenous in their dependency on β 2-glycoprotein I: analysis of anticardiolipin antibodies in leprosy. Lupus 1994; 3: 51521.
  • 51
    Loizou S, Cazabon JK, Walport MJ, Tait D, So AK. Similarities of specificity and cofactor dependence in serum antiphospholipid antibodies from patients with human parvovirus B19 infection and from those with systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1038.
  • 52
    Prieto J, Yuste JR, Beloqui O, Civeira MP, Riez JL, Aguirre V, et al. Anticardiolipin antibodies in chronic hepatitis C: implication of hepatitis C virus as the cause of antiphospholipid syndrome. Hepatology 1996; 23: 199204.
  • 53
    Fiallo P, Nunzi T, Cardo PP. β 2-glycoprotein I-dependent anticardiolipin antibodies as risk factor for reactions in borderline leprosy patients. Int J Lepr Other Mycobact Dis 1998; 66: 3878.
  • 54
    Uthman I, Tabbarah Z, Gharavi AE. Hughes syndrome associated with cytomegalovirus infection. Lupus 1999; 8: 7757.
  • 55
    Ray SK, Putterman C, Diamond B. Pathogenic autoantibodies are routinely generated during the response to foreign antigen: a paradigm for autoimmune disease. Proc Natl Acad Sci U S A 1996; 93: 201924.
  • 56
    El-Roeiy A, Gross WL, Luedemann J, Isenberg DA, Shoenfeld Y. Preferential secretion of a common anti-DNA idiotype (16/6Id) and anti-polynucleotide antibodies by normal mononuclear cells following stimulation with Klebsiella pneumoniae. Immunol Lett 1986; 12: 3139.
  • 57
    Grayzel A, Solomon A, Aranow C, Diamond B. Antibodies elicited by pneumococcal antigens bear anti-DNA–associated idiotype. J Clin Invest 1991; 87: 8426.
  • 58
    Kowal C, Weinstein A, Diamond B. Molecular mimicry between bacterial and self antigen in a patient with systemic lupus erythematosus. Eur J Immunol 1999; 29: 190111.
  • 59
    Albert DA, Weisman MH, Kaplan R. The rheumatic manifestations of leprosy (Hansen disease). Medicine (Baltimore) 1980; 59: 4428.
  • 60
    Hemmerich P, Neu E, Macht M, Peter HH, Krawinkel U, von Mikec ZA. Correlation between chlamydial infection and autoimmune response: molecular mimicry between RNA polymerase major sigma subunit from Chlamydia trachomatis and human L7. Eur J Immunol 1998; 28: 385766.
  • 61
    Wilson WA, Scopelitis E, Michalski JP, Pierangeli SS, Silveira LH, Elston RC, et al. Familial anticardiolipin antibodies and with C4 deficiency genotypes that coexist with MHC DQB1 risk factors. J Rheumatol 1995; 22: 22735.